Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

Clinical trial NCT06427005 · UNKNOWN

Trial details

NCT number: NCT06427005
Sponsor: Meng Qiu
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Fruquintinib S-1 Raltitrexed

Start date: 2023-02-20
Primary completion: 2025-08-18
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.